A Study Assessing HMB-002 in Participants With Von Willebrand Disease

ClinicalTrials.gov ID: NCT06754852

Public ClinicalTrials.gov record NCT06754852. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 24, 2026, 7:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-002 in Participants With Von Willebrand Disease (Velora Pioneer)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a first-in-human (FIH), Phase 1/2, 3-part open-label, dose escalation, safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and efficacy study evaluating HMB-002 in participants with VWD. Part A of the study involves a single ascending dose (SAD) regimen design to establish safety, tolerability, PK, and PD effect. In Part B of the study, the safety and tolerability of repeat dosing will be established prior to cohort expansion to explore efficacy. Part C will evaluate the safety, PK, and PD of a single concomitant dose of HMB-002 and factor concentrate with Type 3 VWD or Type 1 VWD with low residual VWF and FVIII who use factor concentrate as prophylaxis.

Study identification

NCT ID: NCT06754852
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Hemab ApS; Industry
Enrollment: 108 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 16 Years to 69 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 5, 2025
Primary completion: Jun 30, 2027
Completion: Jun 30, 2027
Last update posted: Jun 29, 2026

2025 – 2027

United States locations

U.S. sites: 13
U.S. states: 13
U.S. cities: 13

Facility	City	State	ZIP	Site status
Phoenix Children's Hospital	Phoenix	Arizona	85016	Not yet recruiting
Arkansas Children's Hospital	Little Rock	Arkansas	72202	Not yet recruiting
Children's Hospital of Los Angeles	Los Angeles	California	90027	Not yet recruiting
University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center	Miami	Florida	33136	Not yet recruiting
Emory Children's Center	Atlanta	Georgia	30329	Not yet recruiting
Innovative Hematology, Inc./Indiana Hemophilia and Thrombosis Center	Indianapolis	Indiana	46260	Recruiting
Tulane University School of Medicine	New Orleans	Louisiana	70112	Not yet recruiting
University of Michigan Hospitals, Department of Hemophilia and Coagulation Disorders	Ann Arbor	Michigan	48109	Not yet recruiting
Mayo Clinic - Rochester	Rochester	Minnesota	55905	Not yet recruiting
Oregon Health & Science University	Portland	Oregon	97239	Not yet recruiting
Hemophilia Center of Western Pennsylvania	Pittsburgh	Pennsylvania	15213	Not yet recruiting
The University of Texas Southwestern Medical Center	Dallas	Texas	75390	Not yet recruiting
Washington Institute For Coagulation (WIC)	Seattle	Washington	98101	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06754852, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 29, 2026 · Synced Sep 24, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06754852 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →